and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Other Events. Key Findings: 28-Day Nonhuman Primate (NHP) Study The NHP efficacy study evaluated AN2-502998 administered for 28 days in macaques with naturally-acquired, chronic T. cruzi infection, contracted via triatomine (kissing bug) vectors in their natural habitats, the same vector that transmits the parasite to humans. The Chagas disease vector is increasingly prevalent across the southern half of the U.S. The Company believes that efficacy in naturally infected NHPs is the most clinic…

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Other Events. On April 9, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may issue and sell from time to time, at its option, up to an aggregate of $80 million of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), through Jefferies, acting as the Company’s sales agent. Sales of the shares, if any, will be made pursuant to a Regis…

The filing describes a stock option repricing, which is not related to any management change.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Regulation FD Disclosure. On March 9, 2026, the Company issued a press release announcing the Private Placement, a copy of which is attached as Exhibit 99.1 hereto. The information contained in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company’s filings…

The offer and sale of the Securities and the shares of Common Stock underlying the Pre-Funded Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The Company issued the Securities in reliance on exemptions from registration provided for under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”). The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of: (i) 8,245,611 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and (ii) pre-funded warrants to purchase…

Vice President, Controller and Principal Accounting Officer — Sarah Williams: Sarah Williams was promoted to Vice President, Controller and Principal Accounting Officer.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Unregistered Sales of Equity Securities. Issuance of Pre-Funded Warrants in Exchange for Common Stock On June 17, 2025, AN2 Therapeutics, Inc. (the “Company”) entered into an exchange agreement with Coastlands Capital Partners LP (“Coastlands Capital”), pursuant to which Coastlands Capital exchanged 2,500,000 shares of the Company’s common stock for a pre-funded warrant to acquire 2,500,000 shares of the Company’s common stock. On June 19, 2025, the Company entered into another exchange agree…

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Chief Legal Officer and Chief Operating Officer — Joshua Eizen: Joshua Eizen was promoted to Chief Legal Officer and Chief Operating Officer with additional compensation and equity grants.

Entry into a Material Definitive Agreement. The information set forth under “

Material Modification to Rights of Security Holders. On August 15, 2024, AN2 Therapeutics, Inc. (the “ Company ”) entered into a Rights Agreement between the Company and Equiniti Trust Company, LLC as Rights Agent (as amended from time to time, the “ Rights Agreement ”) that was previously approved by the Board of Directors of the Company. In connection with the Rights Agreement, a dividend was declared of one preferred stock purchase right (individually, a “ Right ” and collectively, the “ R…

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

above, Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024 (the “Transition Date”). Pursuant to the Company’s severance plan, Dr. Eckburg will receive, subject to the execution and delivery of an effective release of claims in favor of the Company and continued compliance with all applicable restrictive covenants, (i) a lump sum amount equal to 75% of his annual base salary and (ii) if Dr. Eckburg timely elects continued group healt…

The filing describes a restructuring, but lacks specific details about departures or promotions.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Other Events. On February 12, 2024, AN2 Therapeutics, Inc. (the “Company”) announced its decision to voluntarily pause Phase 3 enrollment in the Company’s seamless Phase 2/3 clinical trial (“EBO-301”) evaluating epetraborole in treatment-refractory Mycobacterium avium complex (“MAC”) lung disease, pending further data review. The double-blind, placebo-controlled trial has two arms comparing epetraborole plus optimized background regimen (“OBR”) versus placebo plus OBR. The voluntary pause was…